ProPhase Labs (PRPH) Competitors $0.34 -0.02 (-6.34%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRPH vs. KLTO, CLSD, TELO, DTIL, ICCC, VNRX, KLRS, GANX, IFRX, and STTKShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Klotho Neurosciences (KLTO), Clearside Biomedical (CLSD), Telomir Pharmaceuticals (TELO), Precision BioSciences (DTIL), ImmuCell (ICCC), VolitionRx (VNRX), Allovir (KLRS), Gain Therapeutics (GANX), InflaRx (IFRX), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Its Competitors Klotho Neurosciences Clearside Biomedical Telomir Pharmaceuticals Precision BioSciences ImmuCell VolitionRx Allovir Gain Therapeutics InflaRx Shattuck Labs ProPhase Labs (NASDAQ:PRPH) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Does the MarketBeat Community favor PRPH or KLTO? ProPhase Labs received 114 more outperform votes than Klotho Neurosciences when rated by MarketBeat users. CompanyUnderperformOutperformProPhase LabsOutperform Votes11448.93% Underperform Votes11951.07% Klotho NeurosciencesN/AN/A Does the media favor PRPH or KLTO? In the previous week, Klotho Neurosciences had 13 more articles in the media than ProPhase Labs. MarketBeat recorded 16 mentions for Klotho Neurosciences and 3 mentions for ProPhase Labs. Klotho Neurosciences' average media sentiment score of 0.32 beat ProPhase Labs' score of 0.29 indicating that Klotho Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Klotho Neurosciences 2 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in PRPH or KLTO? 9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 20.1% of Klotho Neurosciences shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by company insiders. Comparatively, 26.7% of Klotho Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings & valuation, PRPH or KLTO? Klotho Neurosciences has lower revenue, but higher earnings than ProPhase Labs. Klotho Neurosciences is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$5.85M2.42-$16.78M-$1.26-0.27Klotho NeurosciencesN/AN/A$1.35M-$0.36-5.56 Is PRPH or KLTO more profitable? Klotho Neurosciences has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. Klotho Neurosciences' return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase Labs-217.64% -62.92% -30.22% Klotho Neurosciences N/A N/A -25.89% Which has more risk and volatility, PRPH or KLTO? ProPhase Labs has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500. Comparatively, Klotho Neurosciences has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. SummaryKlotho Neurosciences beats ProPhase Labs on 10 of the 13 factors compared between the two stocks. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.12M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-0.278.6727.2119.96Price / Sales2.42262.53408.49157.63Price / CashN/A65.8538.2534.64Price / Book0.126.597.074.69Net Income-$16.78M$143.75M$3.23B$248.14M7 Day Performance-5.03%0.68%0.68%0.91%1 Month PerformanceN/A11.93%9.59%5.71%1 Year Performance-92.75%4.33%32.02%14.71% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs1.2835 of 5 stars$0.34-6.3%N/A-92.9%$14.12M$5.85M-0.27130Short Interest ↑KLTOKlotho NeurosciencesN/A$1.82+787.8%N/AN/A$59.14MN/A-5.06N/AGap UpHigh Trading VolumeCLSDClearside Biomedical2.6575 of 5 stars$0.76-3.2%$4.80+530.7%-33.2%$59.14M$3.76M-1.6930Positive NewsShort Interest ↓High Trading VolumeTELOTelomir Pharmaceuticals2.0558 of 5 stars$1.98-7.9%$15.00+657.6%-63.7%$58.93MN/A-3.411High Trading VolumeDTILPrecision BioSciences4.1841 of 5 stars$5.30-3.5%$47.00+786.8%-57.2%$58.77M$51.14M88.35200News CoverageICCCImmuCell0.5742 of 5 stars$6.42-1.7%N/A+49.7%$58.02M$27.30M-12.8470Short Interest ↓VNRXVolitionRx2.0196 of 5 stars$0.56+0.5%$3.75+573.6%-13.9%$57.35M$1.31M-1.5580Analyst UpgradeGap UpKLRSAllovirN/A$3.06-7.3%N/AN/A$57.23MN/A0.00110High Trading VolumeGANXGain Therapeutics2.3597 of 5 stars$1.91-0.5%$8.20+329.3%-14.7%$57.20M$50K-1.7420IFRXInflaRx3.431 of 5 stars$0.85+2.4%$6.60+676.5%-49.7%$57.06M$129.75K-0.7960Short Interest ↑Analyst RevisionGap DownSTTKShattuck Labs2.544 of 5 stars$1.19+4.4%$7.50+530.3%-83.9%$57M$4.61M-0.78100Positive News Related Companies and Tools Related Companies KLTO Competitors CLSD Competitors TELO Competitors DTIL Competitors ICCC Competitors VNRX Competitors KLRS Competitors GANX Competitors IFRX Competitors STTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRPH) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
